June 2020
Vol 7 | Issue 315

Q&A with Rick Geoffrion of Cyrano Therapeutics

President & CEO

Principle Series:

Cyrano Therapeutics has developed a nasal spray to treat and restore the sense of smell and flavor in those who have experienced a chronic loss of those senses.


The Company was founded by an experienced healthcare executive after personally experiencing a chronic loss of smell and flavor. The nasal spray has restored his smell and flavor function and he is now leading a mission to bring it to others.


The nasal spray developed by Cyrano has been successfully tested in a 94-patient pilot study with 3 out of 4 patients responding to treatment in an all-comer population. Patients have now been followed out to one year and no significant side effects have been reported. Currently no marketed drug therapy exists for this indication and the company is not aware of any in the pipeline aside from the Cyrano product. An IP portfolio has been established and key patents have been issued.
The Company is seeking up to $7M to fund a double-blind, placebo-controlled, randomized trial to initiate a 505(b)(2) pathway to approval in the USA and advance approval pathways in other major geographies.

Join us for a private Family Office Insights Webinar featuring Cyrano Therapeutics who has developed a nasal spray to treat and restore the sense of smell and flavor in those who have experienced a chronic loss of those senses

 

June 10th, 2020 • 2:15pm-3:15pm EST

Investors Only Please

RSVP HERE REQUIRED 


Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com


How did the Company originate?

Cyrano Therapeutics is a company I founded after personally experiencing a chronic loss of smell and flavor due to the flu. I engaged in a global search for a solution and identified a former NIH scientist, Dr. Henkin, who had the knowledge and experience to develop an intranasal therapy to restore smell and flavor function. The treatment we have developed has restored my smell and flavor function and I am now on a mission to bring it to others.

How large is the opportunity?

The chronic loss of smell and flavor is a condition affecting at least 15 million people in the US alone with a similar incidence in Europe, having a significant impact on quality of life and well-being. Influenza, allergic rhinitis and traumatic brain injury are commonly known causes of chronic smell and flavor loss. In the neurodegenerative disease sector, it is also known that 95% of Parkinson’s patients experience smell and flavor loss, often the first symptom of the disease. Finally, we have recently learned that at least 1 in 2 people who contract COVID-19 will lose their sense of smell/flavor. Although some will recover, we are certain that many will have a long-term deficit in need of treatment.

Has the therapy been evaluated in human studies?

The nasal spray developed by Cyrano has been successfully tested in a 94-patient pilot study with 3 out of 4 patients responding to treatment in an all-comer population. Patients have now been followed out to one year and no significant side effects have been reported. Currently no marketed drug therapy exists for this indication and the company is not aware of any in the pipeline aside from the Cyrano product. An IP portfolio has been established and key patents have been issued.


Rick Geoffrion of Cyrano Therapeutics

Rick Geoffrion is the Co-Founder, President and CEO with more than 30 years of experience as a healthcare executive and entrepreneur. He is a founder of multiple venture-backed private healthcare companies, has raised tens of millions in venture capital and achieved significant exits for a number of them. Rick was a smell and flavor impaired patient who has been successfully treated with the Cyrano therapy. His full profile can be found at: www.linkedin.com/in/rick-geoffrion-64b11b2